Oxford Biomedica PLC Oxford Biomedica form digital framework initiative (2825I)
23 November 2018 - 6:00PM
UK Regulatory
TIDMOXB
RNS Number : 2825I
Oxford Biomedica PLC
23 November 2018
Oxford BioMedica announces new digital framework initiative to
streamline the production of next-generation medicines with cash
injection from Innovate UK
Oxford, UK - 23 November 2018: Oxford BioMedica plc ("OXB" or
"the Group"), a leading gene and cell therapy group, today
announces the formation of a new digital framework initiative to
streamline the production of next-generation medicines.
OXB will invest a total of GBP4 million, supported by a GBP2
million grant from Innovate UK, the UK's innovation agency, in
building digital and robotics capabilities that are designed to
drive improvements in analytical methodology, supply times and cost
of goods. The goal is to increase capacity, reduce the cost of
manufacturing and reduce waste.
The aims of the project are aligned with the UK Government's
Life Sciences Sector Deal to help ensure that the next wave of
breakthrough treatments, innovative medical research and
technologies, and high skill jobs are created in Britain.
OXB is committed to investing in the UK and has recently
announced the expansion of its manufacturing capacity to create an
additional 82,398 sqft facility near its headquarters in Oxford.
This new facility secures Oxford as a bioprocessing centre for OXB
and will create up to 100 new, highly skilled positions at the
Group over the next two years.
John Dawson, Chief Executive Officer of Oxford BioMedica,
commented: "With demand for advanced therapy medicinal products
expected to grow at unprecedented levels, underlined by the
interest received from our current and future potential partners at
OXB, it is imperative that we continue to invest in our technology,
capacity and innovation.
"This new initiative will provide us with digital and robotic
enhancements to maintain our global leading position in the
development and manufacture of lentiviral vector products. This is
important for our own R&D pipeline as well as for our blue-chip
partners as we continue to support the delivery of life-altering
gene therapies to patients around the world."
-Ends-
For further information, please contact:
Oxford BioMedica plc: Tel: +44 (0)1865 783 000
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Sarah MacLeod, Head of Communications
Financial and corporate communications Tel: +44 (0)20 3709 5700
enquiries:
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Olivia
Manser/Laura Thornton
Notes to editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
group focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ), which the Group leverages to develop in vivo and
ex vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Bioverativ, Sanofi, Axovant,
Orchard Therapeutics, Boehringer Ingelheim/UK Cystic Fibrosis Gene
Therapy Consortium/Imperial Innovations, GC LabCell and Immune
Design, through which it has long-term economic interests in other
potential gene and cell therapy products. Oxford BioMedica is based
across several locations in Oxfordshire, UK and employs more than
320 people. Further information is available at
www.oxfordbiomedica.co.uk.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCBTBTTMBTTTLP
(END) Dow Jones Newswires
November 23, 2018 02:00 ET (07:00 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024